David Combarel

Villejuif, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Transplacental transfer of osimertinib and alectinib using an ex vivo human placental perfusion model.

Transplacental transfer of osimertinib and alectinib using an ex vivo human placental perfusion model.

Journal: Placenta
Published: February 25, 2026

Correction: Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.

Correction: Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.

Journal: British journal of cancer
Published: January 20, 2026

Analytical feasibility of linezolid quantification by LC-MS/MS using dried plasma spot microsampling.

Analytical feasibility of linezolid quantification by LC-MS/MS using dried plasma spot microsampling.

Journal: International journal of antimicrobial agents
Published: November 03, 2025

Melanoma targeted therapies dabrafenib and trametinib cross the placental barrier in ex vivo human placental perfusions.

Melanoma targeted therapies dabrafenib and trametinib cross the placental barrier in ex vivo human placental perfusions.

Journal: Journal of the American Academy of Dermatology
Published: March 20, 2025

Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma.

Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma.

Journal: Journal for immunotherapy of cancer
Published: November 23, 2024

Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms.

Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms.

Journal: JTO clinical and research reports
Published: August 29, 2024

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 11, 2024

Reply to: "Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer" and "Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails".

Reply to: "Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer" and "Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails".

Journal: Clinical pharmacology and therapeutics
Published: May 24, 2024

Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.

Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.

Journal: Journal for immunotherapy of cancer
Published: April 23, 2024

Brief Report: Targeted Therapies and Pancreatitis in Patients With Advanced Nonsmall Cell Lung Cancer.

Brief Report: Targeted Therapies and Pancreatitis in Patients With Advanced Nonsmall Cell Lung Cancer.

Journal: Clinical lung cancer
Published: March 05, 2024

Breast cancer survivors' opinion on personalizing endocrine therapy and developing informative tools.

Breast cancer survivors' opinion on personalizing endocrine therapy and developing informative tools.

Journal: NPJ breast cancer
Published: January 30, 2024

Tyrosine kinase inhibitors in cancers: Treatment optimization - Part II.

Tyrosine kinase inhibitors in cancers: Treatment optimization - Part II.

Journal: Critical reviews in oncology/hematology
Published: January 24, 2024
Showing 1-12 of 25

Last Updated: 09/26/2026